SEC 13F Intelligence

Managers / Q4 2024 · view latest →

Vivo Capital, LLC

CIK 0001674712 · 192 LYTTON AVENUE, PALO ALTO, CA, 94301 · 650-688-0818

Reported Value
$893M
Q4 2024
Positions
40
Filings on Record
33
2019–present window
Filed
Feb 13, 2025
original filing

Summary

Vivo Capital, LLC reported $893M in U.S.-listed holdings across 40 positions for Q4 2024.

The portfolio is heavily concentrated: SLNOEUR alone accounts for 31.7% of reported value.

Compared with Q3 2024, the fund opened 4 new positions and exited 7.

Portfolio Metrics

Turnover
+9.0%
vs prior filed quarter
Top-10 Concentration
+73.7%
share of reported value
Largest Position
+31.7%
Soleno Therapeutics
New / Exited
4 / 7
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $783MQ4 ’18Q1 ’19: $1.0BQ2 ’19: $1.1BQ3 ’19: $879MQ4 ’19: $1.4BQ4 ’19Q1 ’20: $1.1BQ2 ’20: $1.4BQ3 ’20: $1.4BQ4 ’20: $2.2BQ4 ’20Q1 ’21: $2.8BQ2 ’21: $2.3BQ3 ’21: $2.2BQ4 ’21: $1.7BQ4 ’21Q1 ’22: $1.5BQ2 ’22: $996MQ3 ’22: $906MQ2 ’23: $1.4BQ2 ’23Q3 ’23: $913MQ4 ’23: $1.2BQ1 ’24: $1.3BQ2 ’24: $1.1BQ2 ’24Q3 ’24: $1.2BQ4 ’24: $893MQ1 ’25: $755MQ2 ’25: $977MQ2 ’25Q3 ’25: $1.2BQ4 ’25: $1.5BQ1 ’26: $1.2Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 82.5%ADR: 13.4%Other: 4.0%
  • Common Stock · 82.5% · $737M
  • ADR · 13.4% · $120M
  • Other · 4.0% · $36M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ACRSAclaris Therapeutics, Inc.NEW+8.89M8.89M+$22M$22M
CDTXCidara Therapeutics, Inc.NEW+670.6K670.6K+$18M$18M
DRUGBright Minds Biosciences IncNEW+251.6K251.6K+$9M$9M
DBVTDBV Technologies SANEW+32.0K32.0K+$98,942$98,942
Unicycive TherapeuticsADDED+5.50M9.97M+$6M$8M
TRVITrevi Therapeutics IncADDED+1.88M3.49M+$9M$14M
HRMYHarmony Biosciences Holdings IncSOLD OUT−2.61M0−$104M$0
Sinovac Biotech Ltd.SOLD OUT−11.80M0−$76M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2024

40 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SLNOEURSoleno Therapeutics Inchistory →Common31.68%$283M6.29M
2VRNAVerona Pharma PLChistory →SPONSORED ADS11.88%$106M2.28M
3GONGeron Corphistory →Common10.80%$96M27.23M
4430Terns Pharmaceuticals Inchistory →Common4.28%$38M6.90M
5Avadel Pharmaceuticals PLCADR3.16%$28M2.68M
6DYNDyne Therapeutics Inchistory →Common2.94%$26M1.11M
7ACRSAclaris Therapeutics, Inc.history →Common2.47%$22M8.89M
8DCTHDelcath Systems, Inc.history →Common2.30%$21M1.71M
9VRDNViridian Therapeutics Inchistory →Common2.11%$19M982.6K
10CDTXCidara Therapeutics, Inc.history →Common2.02%$18M670.6K
11ERASErasca Inchistory →Common1.90%$17M6.76M
12TRVITrevi Therapeutics Inchistory →Common1.61%$14M3.49M
13CATBUSDAstria Therapeutics Inchistory →Common1.56%$14M1.55M
14RZLTRezolute Inchistory →Common1.54%$14M2.80M
15SERASera Prognostics Inchistory →Common1.51%$13M1.65M
16Tourmaline Bio Inc.Common1.34%$12M591.9K
17CRVSCorvus Pharmaceuticals Holdingshistory →Common1.34%$12M2.23M
18TILInstil Bio Inchistory →Common1.25%$11M585.5K
19ORICOric Pharmaceuticals Inchistory →Common1.16%$10M1.28M
20ABEOAbeona Therapeutics, Inc.history →Common1.15%$10M1.84M
21ZBIOZenas Biopharma Inchistory →Common1.09%$10M1.18M
22DRUGBright Minds Biosciences Inchistory →Common1.02%$9M251.6K
23OLMAOlema Pharmaceuticals IncCommon0.98%$9M1.51M
24COGTCogent Biosciences IncCommon0.98%$9M1.12M
25CELCCelcuity IncCommon0.90%$8M610.5K
26VSTMVerastem IncCommon0.89%$8M1.54M
27Unicycive TherapeuticsCommon0.89%$8M9.97M
28RGLSRegulus Therapeutics IncCommon0.89%$8M5.00M
29SLNSilence Therapeutics PLCADS0.85%$8M1.11M
30CMPSCompass Pathway PLCSPONSORED ADS0.68%$6M1.61M
31IOBTQIO Biotech IncCommon0.64%$6M6.17M
32ALGSAligos Therapeutics IncCommon0.63%$6M141.9K
33CMPXCompass Therapeutics IncCommon0.58%$5M3.56M
34ALLKGUSDAllakos IncCommon0.40%$4M2.96M
35CRBPCorbus Pharmaceuticals HoldingsCommon0.22%$2M166.8K
36BOLT1EURBolt Therapeutics IncCommon0.21%$2M3.52M
37TENXTenax Therapeutics IncCommon0.14%$1M208.3K
38DBVTDBV Technologies SASPONSORED ADS0.01%$98,94232.0K
39QTTBQ32 Bio Inc.Common0.01%$70,72320.6K
40DTILPrecision Biosciences IncCommon0.00%$17,8124.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.2B46May 20, 2026RESTATEMENTchanges · EDGAR ↗
Q4 2025$1.5B47Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.2B47Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$977M42Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$755M40May 12, 202513F-HRchanges · EDGAR ↗
Q4 2024$893M40Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.2B43Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.1B42Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$1.3B42Apr 22, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.2B47Feb 7, 202413F-HRchanges · EDGAR ↗
Q3 2023$913M53Nov 8, 202313F-HRchanges · EDGAR ↗
Q2 2023$1.4B48Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023under review48May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022under review48Feb 13, 202313F-HRchanges · EDGAR ↗
Q3 2022$906M51Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$996M49Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.5B54May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.7B55Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.2B60Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.3B59Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.8B63May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$2.2B59Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.4B54Nov 13, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$1.4B54Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.1B53May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.4B49Feb 25, 2020RESTATEMENTchanges · EDGAR ↗
Q3 2019$879M49Nov 13, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.1B46Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.0B49May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$783M45Feb 13, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.